← Evidence map

ArticleVaccines2026

Reply to Hodges et al. Comment on "Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States.

Klodeta Kura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Reply to Hodges et al. Comment on "Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. | Socratic